Current Medicinal Chemistry

ISSN: 0929-8673




Current Medicinal Chemistry
Volume 16, Number 31, 2009

Contents


Extraction of Structure-Activity Relationship Information from High-Throughput Screening Data Pp. 4049-4057
M. Wawer and J. Bajorath
[Abstract] [Purchase Article]


Apoptosis and Human Diseases: Mitochondrion Damage and Lethal Role of Released Cytochrome c as Proapoptotic Protein Pp. 4058-4065
P. Caroppi, F. Sinibaldi, L. Fiorucci and R. Santucci
[Abstract] [Purchase Article]


Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development Pp. 4066-4218
B. Wang and S.-F. Zhou
[Abstract] [Purchase Article]




Abstracts


[Back to top] [Purchase Article]
Extraction of Structure-Activity Relationship Information from High-Throughput Screening Data
M. Wawer and J. Bajorath

The wealth of biological screening data that is generated poses substantial problems to medicinal chemistry. A key question becomes how to best prioritize and select hits for further evaluation from the many weakly active compounds that are typically identified in HTS campaigns. Such decisions can be substantially supported if it is possible to evaluate preliminary structure-activity relationship (SAR) information that might be contained in screening data. If SAR information can be extracted from screening data, one can attempt to estimate the chemical optimization potential of hits. We will discuss different types of approaches that have been developed to facilitate HTS data analysis, with special emphasis on recent methods to explore SAR information contained in screening sets.


[Back to top] [Purchase Article]
Apoptosis and Human Diseases: Mitochondrion Damage and Lethal Role of Released Cytochrome c as Proapoptotic Protein
P. Caroppi, F. Sinibaldi, L. Fiorucci and R. Santucci

Apoptosis is strictly connected to the pathogenesis of many human diseases, including neoplastic, neurodegenerative or cardiovascular diseases. It is a highly programmed cell death which can be activated by various factors. Mitochondria play a key role in the apoptotic process; their damage, which involves permeabilization of the outer mitochondrial membrane, activates a series of events that lead to cell death. Of the two proposed signaling pathways of apoptosis, i.e. the ‘extrinsic’ and the ‘intrinsic’ pathway, the latter is assumed to initiate in mitochondria. Its activation involves release of cytochrome c and other pro-apoptotic factors from the mitochondrial intermembrane space. In the cytosol, cytochrome c exerts its pro-apoptotic action. It binds to the apoptosis protease activation factor (APAf-1) and forms a complex indicated as ‘apoptosome’. The complex-induced activation of pro-caspase 9 initiates an enzymatic reaction cascade leading to the execution of apoptosis in cells. This review provides an overview of the key role played by mitochondria and cytochrome c in the activation of the apoptotic process.


[Back to top] [Purchase Article]
Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development
B. Wang and S.-F. Zhou

Human cytochrome P450 1A2 (CYP1A2) is one of the major CYPs in the liver (~13%) and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a molecular mass of 58,294 Dal. The recently published crystal structure of CYP1A2 in complex with a-naphthoflavone has showed a rather compact active site with a relatively small volume of the cavity of 375 ų, which is 44.2% and 49.3% larger than that of CYP2A6 (260 ų) and CYP2E1 (190 ų), respectively. A series of residues in the substrate recognition regions of CYP1A2 (e.g. Arg108, Thr124, Thr223, Glu225, Phe226, Lys250, Arg251, Lys253, Asn312, Asp313, Glu318, Thr319, Asp320, Thr321, Val322, Leu382, Thr385, and Ile386) have been shown to play important roles in ligand-enzyme binding based on site-directed mutagenesis and homology modeling studies. Typical CYP1A2 substrates generally contain planar ring that can fit the narrow and planar active site of the enzyme, such as propranolol, clozapine, guanabenz, flutamide, imatinib, thalidomide, carbamazepine, lidocaine, theophylline, tacrine, tizanidine, zolpidem, riluzole, zileuton, and leflunomide. CYP1A2 is one of the major enzymes that bioactivate a number of procarcinogens including polycyclic aromatic hydrocarbons (e.g., benzo[a]pyrene), heterocyclic aromatic amines/amides (e.g. 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), mycotoxins (e.g. aflatoxin B₁) and some natural compounds such as aristolochic acids present in several Chinese herbal medicines. This enzyme also metabolizes several important endogenous compounds including retinols, melatonin, steroids, uroporphyrinogen and arachidonic acids. Like many of other CYPs, CYP1A2 is subject to induction and inhibition by a number of compounds. In particular, several therapeutic drugs including antofloxacin, carbamazepine, dihydralazine, furafylline, isoniazid, rofecoxib, clorgyline, thiabendazole, and zileuton are mechanism-based inhibitors of CYP1A2. Reversible and irreversible inhibition of by drugs CYP1A2 may provide an explanation for some clinical drug-drug interactions. Similar to CYP1A1 and 1B1, CYP1A2 is primarily regulated by the aromatic hydrocarbon receptor (AhR), a ligand-activated transcription factor and a basic helix-loop-helix protein belonging to the Per-Arnt-Sim family of transcription factors. CYP1A2 is polymorphic and a number of genetic mutations in CYP1A2 have been reported. It has been suggested that approximately 35 to 75% of the interindividual variability in CYP1A2 activity is due to genetic factors. Some of the mutations of CYP1A2 have been found to alter the clearance of drugs that are extensively metabolized by CYP1A2. Collectively, CYP1A2 plays a major role in drug metabolism, procarcinogen activation and some drug-drug interactions; it is important to identify whether a new drug is a substrate, inducer or inhibitor in drug development. This candidate selection might eventually lead to a less prominent role of this enzyme in the future for drug metabolism and minimize the potential for significant polymorphic metabolism in humans and drug-drug interactions when used in combination with CYP1A2 inhibitors.